Charles River Laboratories

Charles River Laboratories International and Medigen Vaccine Biologics Corp. announced a collaboration to characterize and validate the virus seed bank for Medigen's next-generation multivalent enterovirus vaccine. Charles River will provide advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River's role as a specialized partner for complex biologics testing and regulatory readiness, potentially reinforcing its positioning in high-value vaccine and infectious disease programs. The collaboration slots into an existing narrative of expanding capabilities in biologics and infectious disease work rather than resetting expectations on its own.

Charles River Laboratories International shares have risen 33.3% over the past four weeks, lifted by second-quarter earnings that beat estimates and raised guidance. The company reported non-GAAP earnings of $3.02 per share, down 3.2% year over year but 17.6% above the Zacks Consensus Estimate, while revenues of $1 billion declined 2.7% but topped consensus by 3%. Management raised full-year non-GAAP earnings guidance to $11.15-$11.45 per share from $10.80-$11.30. Discovery and Safety Assessment organic revenues rose 0.2%, the segment's first organic growth since the third quarter of 2023, with net bookings up 12.6% sequentially to $701 million and backlog at $1.97 billion. However, Research Models and Services organic revenues fell 1.4%, and the stock trades at 24.06 times forward earnings versus a five-year median of 18.44 times, leaving less room for execution missteps.

Charles River Laboratories reported second-quarter results that beat analyst estimates and raised its full-year adjusted EPS guidance to $11.30 at the midpoint, a 2.3% increase. Revenue came in at $1.00 billion versus estimates of $979.9 million, a 2.5% beat despite a 2.7% year-on-year decline, while adjusted EPS of $3.02 beat estimates of $2.74 by 10.3%. Management highlighted recovering biopharmaceutical demand, with the Discovery and Safety Assessment segment posting a four-year high net book-to-bill and positive organic revenue growth for the first time since 2023. CEO Birgit Girshick attributed the stabilization to increased proposal activity and improved funding for small and midsize biotech clients, while noting that North American academic and government spending remained subdued. The divestiture of non-core businesses provided an immediate operating margin benefit, lifting operating margin to 11.9% from 9.7% a year earlier.

Charles River Laboratories raised its full-year 2026 guidance after second-quarter results exceeded its prior outlook, driven by improving biopharmaceutical demand and a rebound in its Discovery and Safety Assessment segment. The company reported organic revenue growth of 0.1% for the quarter, the first organic increase since the third quarter of 2023, and non-GAAP earnings per share of $3.02, up 47% sequentially. DSA net bookings rose 12.6% sequentially to $701 million, pushing the net book-to-bill to 1.19x, the highest in nearly four years. Charles River now expects full-year organic revenue growth of flat to 1%, up from a prior forecast of a low single-digit decline, and raised its non-GAAP EPS guidance to a range of $11.15 to $11.45. The company also cited a collaboration with Eli Lilly's TuneLab platform and an expansion of bioanalytical capacity in Scotland as strategic highlights.

The global cell-based assay services for preclinical use only market reached approximately $4.47 billion in 2025 and is projected to grow to $12.93 billion by 2035, according to a new report from ResearchAndMarkets.com. The market recorded a compound annual growth rate of 12.3% from 2020 and is forecast to expand at 11.5% through 2030 before reaching the 2035 figure. Cytotoxicity assays were the largest segment in 2025, accounting for 30.8% of the market, while phenotypic and morphological assays are expected to be the fastest-growing category through 2030. North America led regional revenue with a 40.1% share in 2025, but Asia-Pacific is forecast to be the fastest-growing region with a 15.2% CAGR through 2030. Leading companies profiled include Charles River Laboratories, Labcorp Drug Development, Eurofins Scientific, and Evotec, with the top 10 competitors holding 19.17% of the market in 2024.

Charles River Laboratories announced a collaboration with Arovella Therapeutics to provide Good Manufacturing Practice Next Generation Sequencing services for cell characterization, supporting Arovella's invariant Natural Killer T cell therapy platform for cancer. The FDA has approved the use of NGS for viral safety testing of two cell banks producing reagents for Arovella's lead candidate ALA-101, a CAR-iNKT cell therapy targeting CD19-positive B cell lymphomas and leukemias. Charles River will also perform viral safety release testing on clinical batches of ALA-101. The collaboration aligns with Charles River's strategy to deepen client relationships and accelerate development with alternative methods, and follows its recent acquisition of Pathoquest to enhance NGS capabilities.

Morgan Stanley upgraded Charles River Laboratories International to Overweight from Equalweight and raised its price target to $220 from $185, citing a strong uptick in biopharma funding that is translating into proposals and bookings. The firm expects the company to benefit from its leading preclinical capabilities and sees recent acquisitions and divestitures offering upside risk to Street estimates. Morgan Stanley also moved its 2027 earnings per share estimates up by low single digits, anticipating a notable uptick in safety testing. Separately, CLSA upgraded the stock to Outperform from Hold, buoyed by a more favorable regulatory environment in China.

A bullish thesis on Charles River Laboratories International, Inc. was published on TradersPro's Substack, highlighting improving momentum as demand for outsourced lab services rebounds. The stock was trading at $202.10 as of June 24th, with trailing and forward P/E ratios of 25.07 and 18.15 respectively. The thesis points to biotech and pharmaceutical clients restarting paused development programs, integration of artificial intelligence into early-stage drug discovery, and acquisitions expanding service capabilities. Structural demand is supported by industry outsourcing trends and non-discretionary regulatory safety testing, while technical indicators show rising volume and buyer conviction.

Charles River Laboratories will provide standardized nonclinical testing services to AI/ML-enabled biotech companies using Eli Lilly’s TuneLab drug discovery platform under a collaboration announced in June 2026. The deal embeds Charles River more deeply into Lilly’s Catalyze360 ecosystem, potentially strengthening its role in data-rich, AI-enhanced preclinical research workflows. The collaboration aligns with Charles River’s broader push into technology-enabled services, including its AI-enabled digital pathology platform, but does not materially alter the near-term focus on restoring organic growth and managing demand risk in its Discovery & Safety Assessment segment. While the partnership highlights upside from AI-driven discovery, investors also face longer-term risk that alternative testing methods could erode traditional services.

Charles River Laboratories International is the better buy in 2026 compared to Bio-Rad Laboratories, according to a Motley Fool analysis. Charles River is further along in refocusing its business, with fiscal 2026 revenue projected at $3.9 billion and net income swinging back to profitability at $285 million, while Bio-Rad faces headwinds with expected sales of $2.57 billion and net income dropping to $225 million. Charles River also trades at a cheaper forward P/E of 16.6x versus Bio-Rad's 31.95x, despite Bio-Rad's higher current profitability and stronger balance sheet. Both companies are retooling for growth, but Charles River's progress and valuation give it the edge.

Morgan Stanley upgraded Charles River Laboratories to Overweight and downgraded IQVIA Holdings to Equal-weight on Wednesday, June 17. The bank raised its Charles River price target to $220 from $185, citing increased biopharma funding that benefits the company's higher exposure to small and mid-sized biotech clients, which account for 40% to 45% of its revenue. IQVIA's target was cut to $200 from $225, with Morgan Stanley flagging a risk that pharmaceutical companies could move about 30% of typical trial costs in-house using artificial intelligence, reducing demand for its services. The downgrade also noted that much of IQVIA's earnings growth since 2022 has come from stock buybacks rather than faster sales. In a related transaction, IQVIA is buying European drug discovery assets from Charles River for roughly $145 million in cash, a deal expected to close this quarter.

The global cell and gene therapy CDMO market is projected to grow from $8.3 billion in 2025 to $57.1 billion by 2034, at a compound annual growth rate of approximately 24%, according to a report by DelveInsight. North America held the largest share in 2025, accounting for roughly 40% of the global market, driven by an expanding pipeline of cell and gene therapies and substantial investments in innovative technologies. Key companies in the market include Catalent, Minaris Advanced Therapies, SCTbio, Cellex Cell Professionals, Mycenax Biotech, MedTherapy Biotech, ENCELL, Nucelion Biotechnologies, Charles River Laboratories, Lonza Group, Thermo Fisher Scientific, and WuXi AppTec. Recent developments include Catalent expanding its agreement with Cartherics for iPSC-derived CAR-NK cell therapies in April 2026, and Lonza expanding its manufacturing agreement with Genetix Biotherapeutics for ZYNTEGLO in March 2026. The market growth is fueled by rising numbers of cell and gene therapy candidates, increasing outsourcing trends, and advancements in manufacturing technologies.